SCHEMBL5234919

SCHEMBL5234919

C[C@@]1(Cc2cccc(Cl)c2)NC(=O)CCN(c2cccc3ccccc23)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.37
▸ DRD4 P21917 1/20 0.37
▸ KCNQ2 O43526 2/20 0.36
▸ METAP2 P50579 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ ELANE P08246 1/20 0.36
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ ALDH3A1 P30838 1/20 0.35
▸ P2RX7 Q99572 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ AMPD2 Q01433 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233691 0.89 P2RX7 (0.37) KCNQ2SIGMAR1ELANEGAAP2RX7
SCHEMBL5229569 0.89 P2RX7 (0.37) KCNQ2SIGMAR1ELANEGAAP2RX7
SCHEMBL5237680 0.76 CCR4 (0.32) KCNQ2SIGMAR1ELANEGAAP2RX7
Hydrochloric Acid SCHEMBL5233103 0.64 SIGMAR1 (0.40) SIGMAR1GAAHTR1ADRD2ADRA1D
SCHEMBL13879551 0.64 ITGAL (0.62) KMT2AELANEMAPT
SCHEMBL1626105 0.63 POLB (0.49) KMT2AKDM4ESIGMAR1ELANECYP1A2
SCHEMBL1878252 0.61 POLB (0.47) KMT2AKDM4ESIGMAR1ELANECYP1A2
SCHEMBL11495387 0.60 ITGAL (0.38) KMT2ACYP2C9CYP2C19MAPT
SCHEMBL27284726 0.60 CRBN (0.61) KMT2AKDM4ECYP1A2
SCHEMBL1828595 0.59 ELANE (0.43) KMT2ASIGMAR1ELANEGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP disclosed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 KMT2A 1204/4885KDM4E 3134/4885DRD4 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback